JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

Search

IQVIA Holdings Inc

Ouvert

SecteurSoins de santé

158.69 0.55

Résumé

Variation du prix de l'action

24h

Actuel

Min

153.65

Max

159.22

Chiffres clés

By Trading Economics

Revenu

182M

514M

Ventes

264M

4.4B

P/E

Moyenne du Secteur

20.898

67.147

Marge bénéficiaire

11.778

Employés

93,000

EBITDA

1B

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+41.24% upside

Dividendes

By Dow Jones

Prochains Résultats

5 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-12B

28B

Ouverture précédente

158.14

Clôture précédente

158.69

Sentiment de l'Actualité

By Acuity

50%

50%

201 / 348 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

IQVIA Holdings Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 avr. 2026, 23:53 UTC

Résultats

Naver Posts Weaker First-Quarter Earnings

29 avr. 2026, 23:41 UTC

Actions en Tendance

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 avr. 2026, 23:55 UTC

Résultats

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 avr. 2026, 23:54 UTC

Résultats

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 avr. 2026, 23:52 UTC

Résultats

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 avr. 2026, 23:51 UTC

Résultats

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 avr. 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 avr. 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 avr. 2026, 23:24 UTC

Résultats

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 avr. 2026, 23:24 UTC

Résultats

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 avr. 2026, 23:24 UTC

Résultats

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 avr. 2026, 23:24 UTC

Résultats

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 avr. 2026, 23:22 UTC

Résultats

China Longyuan 1Q Net CNY1.70B, Down 14%

29 avr. 2026, 23:22 UTC

Résultats

China Longyuan: Power Generation Down 2.9% as of End-March

29 avr. 2026, 23:20 UTC

Résultats

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 avr. 2026, 23:20 UTC

Résultats

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 avr. 2026, 23:19 UTC

Résultats

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 avr. 2026, 23:19 UTC

Résultats

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 avr. 2026, 23:19 UTC

Résultats

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 avr. 2026, 23:19 UTC

Résultats

China Vanke 1Q Loss Narrows>000002.SZ

29 avr. 2026, 23:18 UTC

Résultats

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 avr. 2026, 23:17 UTC

Résultats

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 avr. 2026, 23:15 UTC

Résultats

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 avr. 2026, 23:15 UTC

Résultats

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 avr. 2026, 23:13 UTC

Résultats

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 avr. 2026, 23:12 UTC

Résultats

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 avr. 2026, 23:11 UTC

Résultats

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 avr. 2026, 23:11 UTC

Résultats

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 avr. 2026, 23:04 UTC

Résultats

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 avr. 2026, 23:04 UTC

Résultats

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Comparaison

Variation de prix

IQVIA Holdings Inc prévision

Objectif de Prix

By TipRanks

41.24% hausse

Prévisions sur 12 Mois

Moyen 224.54 USD  41.24%

Haut 255 USD

Bas 185 USD

Basé sur 16 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

16 ratings

14

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

150.68 / 153.45Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Neutral Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

201 / 348Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat